Trinity Biotech plc (TRIB)
USD 0.81
(-4.35%)
USD 0.81
(-4.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 67.42 Million USD | 15.74% |
| 2022 | 58.25 Million USD | -41.25% |
| 2021 | 99.15 Million USD | -4.97% |
| 2020 | 104.34 Million USD | 27.21% |
| 2019 | 82.02 Million USD | 0.5% |
| 2018 | 81.62 Million USD | -13.93% |
| 2017 | 94.82 Million USD | -1.73% |
| 2016 | 96.49 Million USD | -1.58% |
| 2015 | 98.04 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 118 Thousand USD | -56.78% |
| 2010 | 273 Thousand USD | -99.14% |
| 2009 | 31.91 Million USD | -11.79% |
| 2008 | 36.18 Million USD | -14.13% |
| 2007 | 42.13 Million USD | -17.36% |
| 2006 | 50.98 Million USD | 87.93% |
| 2005 | 27.12 Million USD | 19.05% |
| 2004 | 22.78 Million USD | 2.59% |
| 2003 | 22.21 Million USD | 186.77% |
| 2002 | 7.74 Million USD | -21.64% |
| 2001 | 9.88 Million USD | 163.23% |
| 2000 | 3.75 Million USD | -70.36% |
| 1999 | 12.66 Million USD | 6.46% |
| 1998 | 11.9 Million USD | 5850.0% |
| 1997 | 200 Thousand USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 100 Thousand USD | -50.0% |
| 1994 | 200 Thousand USD | 0.0% |
| 1993 | 200 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 93.33 Million USD | 8.99% |
| 2024 Q1 | 85.63 Million USD | 27.01% |
| 2023 Q1 | 76.93 Million USD | 32.06% |
| 2023 FY | 67.42 Million USD | 15.74% |
| 2023 Q4 | 67.42 Million USD | 0.61% |
| 2023 Q3 | 67.01 Million USD | -0.46% |
| 2023 Q2 | 67.32 Million USD | -12.48% |
| 2022 Q3 | 57.91 Million USD | -2.49% |
| 2022 Q2 | 59.39 Million USD | -22.32% |
| 2022 Q4 | 58.25 Million USD | 0.6% |
| 2022 FY | 58.25 Million USD | -41.25% |
| 2022 Q1 | 76.45 Million USD | -22.89% |
| 2021 Q1 | 84.04 Million USD | -19.45% |
| 2021 Q3 | 83.15 Million USD | -0.04% |
| 2021 Q4 | 99.15 Million USD | 19.24% |
| 2021 FY | 99.15 Million USD | -4.97% |
| 2021 Q2 | 83.19 Million USD | -1.02% |
| 2020 Q3 | 83.06 Million USD | 0.19% |
| 2020 Q1 | 82.18 Million USD | 0.2% |
| 2020 FY | 104.34 Million USD | 27.21% |
| 2020 Q2 | 82.9 Million USD | 0.87% |
| 2020 Q4 | 104.34 Million USD | 25.62% |
| 2019 FY | 82.02 Million USD | 0.5% |
| 2019 Q4 | 82.02 Million USD | 0.2% |
| 2019 Q3 | 81.86 Million USD | 0.09% |
| 2019 Q2 | 81.79 Million USD | -0.18% |
| 2019 Q1 | 81.94 Million USD | 0.39% |
| 2018 Q1 | 95.16 Million USD | 0.36% |
| 2018 Q2 | 95.17 Million USD | 0.01% |
| 2018 Q3 | 82.05 Million USD | -13.79% |
| 2018 Q4 | 81.62 Million USD | -0.53% |
| 2018 FY | 81.62 Million USD | -13.93% |
| 2017 Q1 | 95.46 Million USD | -1.07% |
| 2017 Q4 | 94.82 Million USD | -0.52% |
| 2017 Q2 | 95.24 Million USD | -0.23% |
| 2017 Q3 | 95.31 Million USD | 0.07% |
| 2017 FY | 94.82 Million USD | -1.73% |
| 2016 Q4 | 96.49 Million USD | -4.8% |
| 2016 Q1 | 100.07 Million USD | 2.07% |
| 2016 Q2 | 99.23 Million USD | -0.84% |
| 2016 Q3 | 101.35 Million USD | 2.14% |
| 2016 FY | 96.49 Million USD | -1.58% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 98.04 Million USD | -1.03% |
| 2015 FY | 98.04 Million USD | 0.0% |
| 2015 Q3 | 99.06 Million USD | -9.21% |
| 2015 Q2 | 109.12 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | 70 Thousand USD | -35.19% |
| 2012 Q2 | 30 Thousand USD | -57.14% |
| 2012 FY | - USD | -100.0% |
| 2011 Q2 | 210 Thousand USD | -15.32% |
| 2011 Q1 | 248 Thousand USD | -9.16% |
| 2011 Q4 | 108 Thousand USD | -28.95% |
| 2011 Q3 | 152 Thousand USD | -27.62% |
| 2011 FY | 118 Thousand USD | -56.78% |
| 2010 Q2 | 1.14 Million USD | -96.16% |
| 2010 Q1 | 29.87 Million USD | -6.39% |
| 2010 FY | 273 Thousand USD | -99.14% |
| 2010 Q4 | 273 Thousand USD | -41.91% |
| 2010 Q3 | 470 Thousand USD | -59.02% |
| 2009 Q4 | 31.91 Million USD | 0.03% |
| 2009 Q3 | 31.9 Million USD | -7.82% |
| 2009 FY | 31.91 Million USD | -11.79% |
| 2009 Q2 | 34.61 Million USD | 1.36% |
| 2009 Q1 | 34.14 Million USD | -5.62% |
| 2008 FY | 36.18 Million USD | -14.13% |
| 2008 Q3 | 36.42 Million USD | -3.49% |
| 2008 Q4 | 36.18 Million USD | -0.67% |
| 2008 Q2 | 37.74 Million USD | -0.46% |
| 2008 Q1 | 37.91 Million USD | -10.0% |
| 2007 Q4 | 42.13 Million USD | 0.0% |
| 2007 Q2 | 39.35 Million USD | 0.17% |
| 2007 FY | 42.13 Million USD | -17.36% |
| 2007 Q1 | 39.29 Million USD | -22.93% |
| 2006 Q1 | 24.03 Million USD | -11.39% |
| 2006 FY | 50.98 Million USD | 87.93% |
| 2006 Q4 | 50.98 Million USD | 8.38% |
| 2006 Q3 | 47.04 Million USD | -9.3% |
| 2006 Q2 | 51.86 Million USD | 115.78% |
| 2005 FY | 27.12 Million USD | 19.05% |
| 2005 Q2 | 19.34 Million USD | -10.26% |
| 2005 Q1 | 21.55 Million USD | -5.42% |
| 2005 Q4 | 27.12 Million USD | 4.59% |
| 2005 Q3 | 25.93 Million USD | 34.1% |
| 2004 FY | 22.78 Million USD | 2.59% |
| 2004 Q4 | 22.78 Million USD | 29.57% |
| 2004 Q3 | 17.58 Million USD | 0.37% |
| 2004 Q2 | 17.52 Million USD | 0.33% |
| 2004 Q1 | 17.46 Million USD | -21.37% |
| 2003 Q1 | 7.03 Million USD | -9.15% |
| 2003 Q2 | 4.91 Million USD | -30.23% |
| 2003 FY | 22.21 Million USD | 186.77% |
| 2003 Q3 | 20 Million USD | 307.33% |
| 2003 Q4 | 22.21 Million USD | 11.06% |
| 2002 Q3 | 6.7 Million USD | -1.47% |
| 2002 Q2 | 6.8 Million USD | -10.53% |
| 2002 Q4 | 7.74 Million USD | 15.6% |
| 2002 Q1 | 7.6 Million USD | -23.11% |
| 2002 FY | 7.74 Million USD | -21.64% |
| 2001 Q2 | 4.77 Million USD | 117.09% |
| 2001 Q1 | 2.2 Million USD | -41.41% |
| 2001 Q4 | 9.88 Million USD | 102.51% |
| 2001 FY | 9.88 Million USD | 163.23% |
| 2001 Q3 | 4.88 Million USD | 2.2% |
| 2000 Q1 | - USD | -100.0% |
| 2000 FY | 3.75 Million USD | -70.36% |
| 2000 Q4 | 3.75 Million USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 Q4 | 12.66 Million USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | -100.0% |
| 1999 FY | 12.66 Million USD | 6.46% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | 11.9 Million USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 FY | 11.9 Million USD | 5850.0% |
| 1997 FY | 200 Thousand USD | 0.0% |
| 1997 Q4 | 200 Thousand USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | -50.0% |
| 1994 FY | 200 Thousand USD | 0.0% |
| 1994 Q1 | 200 Thousand USD | 0.0% |
| 1993 FY | 200 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 87.94 Million USD | 23.332% |
| Prenetics Global Limited | 2.36 Million USD | -2745.756% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -1768.301% |
| CareDx, Inc | 34.22 Million USD | -97.034% |
| Exact Sciences Corporation | 2.55 Billion USD | 97.361% |
| Exagen Inc. | 23.72 Million USD | -184.25% |
| Inotiv, Inc. | 417.64 Million USD | 83.855% |
| Guardant Health, Inc. | 1.35 Billion USD | 95.019% |
| Biodesix, Inc. | 60.69 Million USD | -11.099% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -50446.872% |
| Precipio, Inc. | 1.11 Million USD | -5941.846% |
| iSpecimen Inc. | 196.24 Thousand USD | -34258.757% |
| Natera, Inc. | 441.99 Million USD | 84.745% |
| Aspira Women's Health Inc. | 2.26 Million USD | -2875.596% |
| Standard BioTools Inc. | 98.21 Million USD | 31.344% |
| 23andMe Holding Co. | 76.51 Million USD | 11.877% |
| Castle Biosciences, Inc. | 15.31 Million USD | -340.411% |
| Personalis, Inc. | 48.96 Million USD | -37.713% |
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -15727.934% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -5347.502% |
| OpGen, Inc. | 13.04 Million USD | -416.931% |
| T2 Biosystems, Inc. | 49.49 Million USD | -36.222% |
| Myriad Genetics, Inc. | 145 Million USD | 53.499% |
| ICON Public Limited Company | 3.93 Billion USD | 98.288% |
| NeoGenomics, Inc. | 611.67 Million USD | 88.977% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -1768.301% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 92.887% |
| RadNet, Inc. | 1.49 Billion USD | 95.478% |
| MDxHealth SA | 41.26 Million USD | -63.4% |
| Psychemedics Corporation | 2.29 Million USD | -2834.16% |
| Illumina, Inc. | 2.26 Billion USD | 97.019% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 94.06 Million USD | 28.322% |
| DarioHealth Corp. | 29.54 Million USD | -128.249% |
| Fulgent Genetics, Inc. | 14.9 Million USD | -352.318% |
| Sera Prognostics, Inc. | 1.85 Million USD | -3529.01% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -16995.965% |
| OPKO Health, Inc. | 326.56 Million USD | 79.353% |
| Medpace Holdings, Inc. | 142.12 Million USD | 52.557% |
| Neogen Corporation | 906.23 Million USD | 92.56% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -7637.423% |
| Prenetics Global Limited | 2.36 Million USD | -2745.756% |
| Mainz Biomed B.V. | 7.42 Million USD | -808.624% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -4171.211% |
| Neuronetics, Inc. | 62.47 Million USD | -7.928% |
| Sotera Health Company | 2.32 Billion USD | 97.102% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -4171.211% |